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Abstract  
BACKGROUND: Factor V Leiden, Prothrombin and MTHFR gene mutation, could have an 
influence in pregnancy with adverse outcome Preeclamsia, IUGR and Placental abruption.  
AIM: The aim of this study is to investigate the presence of above mentioned inherited 
thrombophilias and its statistical significance, distribution among the complicated and normal 
pregnancy, and relative risk for carrier of mutation to develop preeclampsia, IUGR and placental 
abruption. 
MATERIAL AND METHODS: Prospective cohort study is implemented at University Clinic for 
Obstetric and Gynecology in Skopje, Republic of Macedonia. The study included 109 delivered 
patients: 40 with preeclapmsia, 22 with IUGR, 17 with placental abruption and 30 as control group 
with normal pregnancy. The amount of 3 ml venous blood has been used for detection of these 
point mutations using ThromboStrip -Opegen, QIAGEN kit manufactured for thrombotic risk. 
RESULTS: The highest frequency was found: in the group with preeclampsia 35% were MTHFR 
homozygous, IUGR -MTHFR heterozygous 45%, Placental abruption- 52.9% MTHFR 
heterozygous, and in the control group without thrombophilia 56.7%. There were combined 
thrombophilia in 3 patients. There aren`t statistical significance in presence of thrombophilia among 
groups (p > 0.05). Statistical significance (p < 0.05) was found between carriers of MTHFR 
homozygous in preeclampsia and group with placental abruption and control group. Relative risk in 
IUGR group for MTHFR homozygous was 5.54 (1.37<RR<22.4). Relative risk in placental abruption 
for Factor V Leiden heterozygous was 4.50 (0.47<RR<42.75). 
CONCLUSION: The presence of mutation MTHFR homozygous could increase the risk for 
development of IUGR and mutation of Factor V Leiden for placental abruption. Further 
investigations with more patients are warranted. 
 
 
 
 
 
Introduction 
 
Adequate fetomaternal circulating system is 
essential for normal development and function of 
placenta. It is obtained with mechanism which 
prevents coagulation of the maternal blood around 
chorionic villas and fetal blood in them [1]. Normal 
pathway in coagulation cascade includes balance 
between procoagulants, anticoagulant and fibrinolytic 
components in blood. Depend of the type of inherited 
thrombophilia, there is impaired neutralization of 
thrombin or failure to control generation of thrombin 
[2, 3]. This will cause malfunction of natural 
anticoagulants that maintain the fluidity of the blood. 
In normal circumstances, activated Factor V has 
procoagulant and anticoagulant activity in the same 
time. Activated Protein C inactivates factors Va and 
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VIIIa and limiting the generation of thrombin. When 
gene for synthesis of factor V is mutated, there is 
Arg506Gln substitution, and one of the three cleavage 
sites for activated Protein C is inactive, without 
proteolysis inactivation of factor V.  
On the other side factor V and factor VIII have 
augmentation effect for conversion of prothrombin to 
thrombin. Final effect is increased generation of 
thrombin and in vitro resistance to activated protein C 
to prolong activated partial-thromboplastine time [4, 
5]. Mutation G20210A in 3` untranslated region of 
Prothrombin gene is associated with an increase level 
of plasma Prothrombin and consecutive excessive 
thrombin generation. In homozygous, hyperhomo-
cisteinemia is as a result of C677T mutation in the 
gene for synthesis of MTHFR, lead to synthesis of 
thermo labile molecule of protein MTHFR with 
decrease enzyme activity in conversion of 
homocistein to metionin.  
The pathogenesis for thrombophilia due to 
this mutation is still unknown [6]. The frequency of FV 
Leiden in white healthy individuals is 1%-15% in 
heterozygous and less than 1 % in homozygous [6, 7]. 
In Macedonia the frequency is 5.5% in general 
population, with difference between Macedonian 
population 6.9% and 2.9% in Albanian population, 
without statistical significant difference between the 
males and females [8]. Prothrombin gene mutation is 
2.7%-7% and for MTHFR 5%-15% homozigous 
manner, and in 30-50% in heterozygous manner [9, 
10]. These inherited thrombophilia substantially 
increased the risk for deep venous thrombosis and 
pulmonary thrombembolism during pregnancy and 
puerperium. Also they increase the risk for fetal loss 
after 20 weeks of gestation, especially after 28 weeks. 
In one more general study, it was found presence of 
52% in pregnancy with preeclampsia, IUGR, placental 
abruption and stillbirth and they were heterozygous for 
Factor V Leiden, prothrombin gen mutation or 
homozygous for MTHFR gene mutation, as compared 
with 17% total of controls [11-13]. 
The aim of this study is to investigate the 
presence of above mentioned inherited thrombophilias 
and its statistical significance, distribution among the 
complicated and normal pregnancy, and relative risk 
for carrier of mutation to develop preeclampsia, IUGR 
and placental abruption. 
 
 
Material and Methods 
 
This study was submitted and approved by 
the Ethical Review Committee of the Medical 
University in Skopje and is in adherence to the laws 
and regulations of the country in which the research 
was conducted. Written consent with patient 
permission was obtained from each patient. 
This prospective cohort study was conducted 
at the University Clinic for Obstetric and Gynecology 
in Skopje, included 109 successively admitted and 
delivered patients during period of one year form 
March 2014 to March 2015. All delivered neonates 
were without sign of congenital infection, malformation 
and chromosomopathies. 
The patients were distributed in four groups. 
The first group was consist from 40 patients with 
preeclamsia (PE), second group from 22 patients with 
intrauterine growth restriction (IUGR), third group from 
17 patients with placental abruption (AP) and 30 
patients as a control group of normal pregnancies and 
term spontaneous delivered healthy neonates. 
Inclusion criteria for PE was presence of proteinuria at 
least 0.5 g/L/24 hours, increase in systolic pressure 
for minimum 30 mmHg, and diastolic pressure 15 
mmHg, measured two times apart for six hours, 
compared with blood pressure before pregnancy. 
Exclusion criteria were underlying pre existential 
morbidity: chronic hypertension, diabetes, renal 
disease, autoimmune and metabolic disease (NICE 
guidelines). Inclusion criteria for IUGR were birth 
weight less than 5
th
 percentile for gestational age and 
sex and exclusion criteria were presence of congenital 
infection, anomalies and chromosomopathies and 
mother who took medication, alcohol and with 
toxicomania. The placental abruption was clinically 
and/or histopatologicaly proven and exlusion criteria 
were rupture of membrane, uterine fibroid or other 
operation of uterus [13]. The differences between the 
numbers of participating patient are due to different 
frequency of each clinical entity. PE occurred in 8%-
10%, IUGR 2%-3% and placental abruption 0.5%. 
During that period there were 5600 delivered patients 
in our clinic. 
 
Methods 
After delivery, 3 ml venous blood was taken 
from each patient with vacumtainer in epruvete with 
anticoagulant EDTA, and send to laboratory at 
Institute for Transfusion Medicine. For detection of 
mutations the laboratory used test: ThromboStrip-
Opegen, from QIAGEN (molecular and immune 
diagnostic).This is a test for point gene mutations 
associated with venous thrombotic risk. ThromboStrip 
can detect three point mutations: G1691A for factor V, 
G20210A for prothrombin gene and C677T mutation 
for MTHFR gene. The procedure consists of these 
successive steps: DNA extraction, PCR amplification, 
hybridization, strip developing and detection. DNA 
extraction is manually from leucocytes from venous 
blood (spin protocol) with saline precipitation. After 
that, checking is preformed on 3% agarose gel for the 
presence fragments of free DNA. PCR was conducted 
on Ependorf (amplification of DNA fragments). Test 
membrane carried covalently attached DNA probes 
which specifically could recognize every gene 
amplificated sequence. There are two probe carriers 
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for each gene –one normal and one mutated. The 
next phase is hybridization detection on machine 
AutoLipa 48, where probe carrier is specific attached 
for DNA fragments. The blue precipitation is shown at 
the place where hybridisation is. There are three 
possible results: no mutation, homozygous or 
heterozygous and it compares with control probe 
ThromboStrip on 3% agarous gel. Depends of 
appearance of blue band: one or two bands on test 
probe, the mutation are detected (Fig. 1). Sensitivity 
and specificity are limited only from the amount of 
DNA specimens (if there are 100 DNA fragments, 
compared with other methods, results concordant is 
100%). 
 
 
Figure 1: Example of genotyping using ThromboStripqvality control 
 
Statistical method 
SPSS V.20 was used for numeric and 
attributive paramatetars. Standard descriptive and 
analythical bivariant and multivariant methods were 
used. Statistical significans among attributive 
parameters was determined wit Chi-square test, and 
numerical parameters with Student’s t test. 
 
 
Results 
 
A total of 109 patients were analyzed in this 
study. The patients were distributed in four groups - 
40 patients with preeclampsia (PE), II- 22 patients 
with intrauterine growth restriction (IUGR), III- 17 
patients with placental abruption (AP) and IV-30 
patients as a control group of normal pregnancies and 
term spontaneous delivered healthy neonates. 
Demographic data are presented: patient age-
years (see Table 1) and ethnicity (see Table 2).  
Table 1: Age distribution 
Group Mean No SD. Minium Maximum 
I 29.4 40 6.9 18.0 43.0 
II 31.2 22 5.8 21.0 42.0 
III 31.5 17 5.7 20.0 42.0 
IV 30.1 30 4.2 22.0 41.0 
Total 30.3 109 5.8 18.0 43.0 
 
The differences between mean values in 
patient age in four groups aren’t statistical significant 
(F=0.730792, p=0.54). 
Table 2: Ethnical distribution 
Ethnicity/group I II III KG-IV 
N % N % N % N % 
Macedonians 18 45.0 7 31.8 7 41.2 19 63.3 
Albanians 18 45.0 14 63.7 8 47.0 6 20.0 
Gypsy 3 7.5 0 0 0 0 2 6.7 
Bosnians 1 2.5 1 4.5 1 5.9 3 10.0 
Turkish 0 0 0 0 1 5.9 0 0 
Total 40 100.0 22 100.0 17 100.0 30 100.0 
 
The percent of Albanian and Gipsy population 
in the group with PE is above of their presence in 
national structure of population in Macedonia. In 
control group - 63.3% is Macedonian, Albanians - 
20.0%, Gipsy - 6.7% and Bosnians - 10.0%. This 
distribution is similar with national structure of 
population in Macedonia. 
Distribution of patient’s combination of clinical 
entities and presence of thrombophilia are presented 
in Table 3 and Figure 2. 
Table3: Distribution of patient’s combination of clinical entities 
and presence of thrombophilia 
Thrombophilia type I=40 II==22 III=17 IV=30 
N % N % N % N % 
No  8 20.0 5 22.7 6 35.3 17 56.7 
MTHFR heterozigous 12 30.0 10 45.5 9 52.9 10 33.3 
MTHFR homozigous 14 35.0 7 31.8 1 5.9 2 6.7 
Prothrombin heterozigous 4 10.0 1 4.5 1 5.9 0 0 
Factor V Leiden heterozigous 2 5.0 1 4.5 2 11.8 1 3.3 
 
In the group with preeclampsia 35% of patient 
were MTHFR homozygous, 30% MTHFR 
heterozygous, Prothrombin heterozygous 10%, FV 
Leiden 5% heterozygous and without thrombophilia 
20%. 
In the group with IUGR, 31.8% of patient were 
MTHFR homozygous, 45.5% MTHFR heterozygous, 
Prothrombin heterozygous and FV Leiden 
heterozygous 4.5% (coinheritance) and without 
thrombophilia 22.7%. 
In the group with placental abruption, 5.9% of 
patient were MTHFR homozygous and prothrombin 
heterozigous (coinheritance), 52.9% MTHFR 
heterozygous, FV Leiden heterozygous 11.8% and 
without thrombophilia 35.3%. 
In control group (healthy individuals) 6.7% of 
patient were MTHFR homozygous, 33.3% MTHFR 
heterozygous, FV Leiden 3.3% heterozygous and 
without thrombophilia 56.7%. Differences in 
frequencies present thrombophilia among four groups 
are without statistical significance for p >0.05. 
There was coinheritance in two patients in 
group with IUGR: one with MTHFR homozygous, 
Prothrombin heterozygous and FV Leiden 
heterozygous. Another patient from the same group 
has coinheritance of MTHFR and protrombin 
heterozygous.  
 Livrinova et al. Factor V Leiden, Prothrombin and MTHFR Mutation in Preeclamsia, Intrauterine Growth Restriction and Placental Abruption 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2015 Dec 15; 3(4):590-594.                                                                                                                                                                         593 
 
 
Figure 2: Distribution of patient’s combination of clinical entities and 
presence of thrombophilia 
 
The third patient with coinheritance - MTHFR 
and FV Leiden heterozygous was in the group with 
placental abruption. 
Statistical significance for p<0.05 was found in 
MTHFR homozygous between group with 
preeclampsia and placental abruption and control 
group. Statistical significance for p<0.05 was found in 
absence of thrombophilia between control group and 
the group with placental abruption and preeclampsia. 
RR in PE group for MTHFR heterozygous, 
MTHFR homozygous and FV Leiden heterozygous 
was 1.7, 2.73 and 3.06 respectively. RR in IUGR 
group for MTHFR heterozygous, MTHFR homozygous 
and F V Leiden heterozigous was 1.8, 5.54 and 2.2 
respectively. RR in group with placental abruption for 
MTHFR heterozygous, MTHFR homozygous and FV 
Leiden heterozygous was 1.62, 1.36 and 4.5 
respectively. 
Table 4: Multiple regression analysis 
Independent variables 
r = 0.274, r
2
 = 0.075 
F = 2.841, p = 0.041 
Beta t – test p - level 
Age -0.062399 -0.638054 0.525 
Poor obstetric background -0.040180 -0.416275 0.678 
Positive familial anamnesis 0.272288 2.862150 0.005 
*statistical significant (importance). 
 
Statistical insignificancy between ethnical 
origin and type of thrombophilia was found in the 
group with preeclampsia and IUGR.In the third group 
with placental abruption, depends exists of ethnic 
origin and thrombophilia, with p<0.05, in Albanian 
population. 
The differences among thrombophilia in the 
means value for age of patients is without statistical 
signifignance (P>0.05) 
With multiple regression analysis it was 
concluded correlation between thrombophilia (criteria 
depend variable) and system of predictor’s variables 
of interest: age, familiar anamnesis and obstetrical 
history (independent variables), coefficient of multiple 
correlations (r) is 0.274. Coefficient of determination 
(r
2
) is 0.075, shown that all independent variables 
together have an influence in variability of 
thrombophilia with 7.5%, unless 92.5% belong to 
influence of other factors. Importance of multiple 
correlation coefficient tested on the base of F -
distribution, shown the fact that influence of the 
predicators system of variables on thrombophilia 
(depend variable), is statisticaly significant for p = 
0.041. 
With analysis of each variables, it was 
concluded that important role has positive familiar 
anamnesis for p = 0.005. 
 
 
Discussion 
 
The impact of inherited thrombophilia in 
pregnancy is investigated from many authors. Broad 
spectre of results could be found in literature. Review 
articles clearly shown the reasons for that finding. The 
most of them include patients with eclampsia, HELLP 
syndrome, severe PE, IUGR and placental abruption 
who were delivered in tertiary care hospitals. 
Comparing the results from this study, it could 
be concluded that in healthy individuals the most 
frequent mutation is for MTHFR heterozigous, which 
is similar with the studies from other authors [17] but 
without thrombophilia were 56.7%, compared with the 
study of Kumferminc -80%. It was found no statistical 
significant difference between ethnical origin and 
thrombophilia in population in Macedonia [8]. 
Factor V Leiden mutation increased the risk 
for Preeclampsia has RR form 2.2-6.1 [6, 13-15] 
compared with RR-3.06 in this study. The most of the 
studies included patients with PE before 34 gw [16]. 
The relative risk for carriers of Factor V 
Leiden mutation was 4.5 in the group with placental 
abruption, but without statistical significance for other 
mutations. 
Statistical significance for p<0.05 was found in 
MTHFR homozygous between group with 
preeclampsia and placental abruption and control 
group. 
Statistical significance for p<0.05 was found in 
absence of thrombophilia between control group and 
the group with placental abruption and preeclampsia. 
The relative risks for IUGR for mutation: FV Leiden 
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and Prothrombin are 2.58 and 2.03, p>0.05 [18, 22]. 
Only consistent result was found between 
carrier of FV Leiden homozygous and combined gene 
mutations and deep venous thrombosis in pregnancy 
and puerperium, where the risk increase to 40 folds 
[19-21]. 
In patients with placental abruption, was 
found RR of 3.9-5.0 for Factor V Leiden mutation [12, 
22, 24]. 
These differences in the results probably are 
due to different inclusion criteria, the number of 
patients and selection bias and also because of 
ethnical background of some thrombophilia [23]. 
In conclusion, thrombophilia still remain field 
for further investigations, because a lot of studies 
shown that clinical expression in patients with 
thrombophilia are an interrelation between gene-age-
environmental circumstances. It is important because 
the doctor should be offered screening for the patients 
with risks to develop complications in pregnancy [25]. 
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